Literature DB >> 8342602

K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

R H Hruban1, A D van Mansfeld, G J Offerhaus, D H van Weering, D C Allison, S N Goodman, T W Kensler, K K Bose, J L Cameron, J L Bos.   

Abstract

We examined 82 surgically resected or biopsied, formalin-fixed, paraffin-embedded primary adenocarcinomas of the pancreas for the presence of activating point mutations in codon 12 of the K-ras oncogene. Mutations were detected using primer-mediated, mutant-enriched, polymerase chain reaction-restriction fragment length polymorphism analysis and characterized further by allele-specific oligonucleotide hybridization. This combination of mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis and allele-specific oligonucleotide hybridization results in a rapid and sensitive characterization of the mutations in codon 12 of K-ras. Sixty-eight (83%) of the 82 carcinomas examined harbored a point mutation. Of the 68 mutations, 33 (49%) were guanine to adenine transitions, 27 (39%) were guanine to thymine transversions, and eight (12%) were guanine to cytosine transversions. Mutations were found in carcinomas of the head (61 of 75, 81%) as well as in carcinomas of the body or tail (seven of seven, 100%) of the pancreas. The overall prevalence of K-ras point mutations in adenocarcinomas of the pancreas obtained from patients who smoked cigarettes at some point during their lives (88%; 86% in current smokers and 89% in ex-smokers) was greater than that seen in pancreatic adenocarcinomas from patients who never smoked cigarettes (68%, P = 0.046). The presence of K-ras point mutations did not correlate with tumor ploidy, tumor proliferating index, or patient survival. These results demonstrate that primer-mediated, mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis combined with allele-specific oligonucleotide hybridization can be used to detect and characterize mutations in codon 12 of the K-ras oncogene in formalin-fixed, paraffin-embedded tissues, and the results confirm that activating point mutations in codon 12 of the K-ras oncogene occur frequently in adenocarcinomas of the pancreas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8342602      PMCID: PMC1887038     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists.

Authors:  P K Mills; W L Beeson; D E Abbey; G E Fraser; R L Phillips
Journal:  Cancer       Date:  1988-06-15       Impact factor: 6.860

2.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

Review 3.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

Review 4.  DNA repair, oncogenes and carcinogenesis.

Authors:  M D Topal
Journal:  Carcinogenesis       Date:  1988-05       Impact factor: 4.944

5.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Authors:  V T Smit; A J Boot; A M Smits; G J Fleuren; C J Cornelisse; J L Bos
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

6.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.

Authors:  D Sidransky; T Tokino; S R Hamilton; K W Kinzler; B Levin; P Frost; B Vogelstein
Journal:  Science       Date:  1992-04-03       Impact factor: 47.728

7.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

8.  Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines.

Authors:  A Rivenson; D Hoffmann; B Prokopczyk; S Amin; S S Hecht
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

9.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Authors:  C Almoguera; D Shibata; K Forrester; J Martin; N Arnheim; M Perucho
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

10.  Pancreas cancer and smoking, beverage consumption, and past medical history.

Authors:  T M Mack; M C Yu; R Hanisch; B E Henderson
Journal:  J Natl Cancer Inst       Date:  1986-01       Impact factor: 13.506

View more
  191 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Simple method for DNA extraction from pancreatic juice for PCR amplification assays.

Authors:  P Müller; R Jesnowski; S Liebe; A Rolfs; M Löhr
Journal:  Int J Pancreatol       Date:  1999-02

3.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

4.  K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells.

Authors:  S Y Song; I M Meszoely; R J Coffey; J A Pietenpol; S D Leach
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

5.  Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Brandy Edenfield; Lizhi Zhang; David W Dawson; Peter Storz
Journal:  Cancer Discov       Date:  2014-10-31       Impact factor: 39.397

6.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 7.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 8.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

Review 9.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

10.  Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing.

Authors:  J Ihalainen; M Taavitsainen; T Salmivaara; A Palotie
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.